Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
401 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01743989 | A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.(ENESTPath) | completed | Phase 3 | 620 | Novartis PharmaceuticalsINDUSTRY | 21 | Jul 15, 2021 | clinicaltrials |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | withdrawn | Phase 3 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER |
| 3 |
| Jul 15, 2021 |
| clinicaltrials |
| NCT02599402 | Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma(CheckMate 401) | completed | Phase 3 | 533 | Bristol-Myers SquibbINDUSTRY | 12 | Jun 15, 2021 | clinicaltrials |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting(NALA) | completed | Phase 3 | 621 | Puma Biotechnology, Inc.INDUSTRY | 28 | Jun 11, 2021 | clinicaltrials |
| NCT02130557 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 3 | 536 | PfizerINDUSTRY | 26 | May 18, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT03664869 | Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer(FB10) | unknown | Phase 3 | 300 | Turku University HospitalOTHER_GOV | 1 | Apr 1, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT01271712 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)(GRID) | completed | Phase 3 | 199 | BayerINDUSTRY | 17 | Jan 29, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | completed | Phase 3 | 829 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 17, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT00822393 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | completed | Phase 3 | 570 | medac GmbHINDUSTRY | 6 | Jul 30, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT00006229 | Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 774 | NCIC Clinical Trials GroupNETWORK | 14 | Apr 6, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01212991 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer(PREVAIL) | completed | Phase 3 | 1,717 | PfizerINDUSTRY | 22 | Mar 17, 2020 | clinicaltrials |
| NCT00069121 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | completed | Phase 3 | 1,886 | Hoffmann-La RocheINDUSTRY | 29 | Mar 6, 2020 | clinicaltrials |
| NCT02301624 | Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis | completed | Phase 3 | 117 | Alexion Pharmaceuticals, Inc.INDUSTRY | 17 | Feb 5, 2020 | clinicaltrials |
| NCT02008227 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy(OAK) | completed | Phase 3 | 1,225 | Hoffmann-La RocheINDUSTRY | 31 | Dec 20, 2019 | clinicaltrials |
| NCT00636168 | Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma | completed | Phase 3 | 1,211 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2019 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | completed | Phase 3 | 1,212 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00937950 | Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects | completed | Phase 3 | 2,022 | GlaxoSmithKlineINDUSTRY | 13 | Oct 29, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | completed | Phase 3 | 1,072 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 25, 2019 | clinicaltrials |
| NCT00087711 | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 3 | 1,713 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 12, 2019 | clinicaltrials |
| NCT00137995 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | completed | Phase 3 | 481 | Lymphoma Study AssociationOTHER | 10 | Aug 28, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT01039376 | Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy(PROLONG) | terminated | Phase 3 | 480 | Novartis PharmaceuticalsINDUSTRY | 25 | Jul 30, 2019 | clinicaltrials |
| NCT01997229 | Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | completed | Phase 3 | 125 | Alexion Pharmaceuticals, Inc.INDUSTRY | 21 | Jul 16, 2019 | clinicaltrials |
| NCT01310894 | Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.(PCM301) | completed | Phase 3 | 413 | Steba Biotech S.A.OTHER | 10 | Jul 11, 2019 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT00646854 | Alemtuzumab and CHOP in T-cell Lymphoma(ACT-1) | completed | Phase 3 | 136 | Aarhus University HospitalOTHER | 11 | Mar 1, 2019 | clinicaltrials |
| NCT00639210 | BREAST CANCER AND EXERCISE(BREX) | completed | Phase 3 | 573 | Finnish Breast Cancer GroupOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01633060 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi(BELLE-3) | terminated | Phase 3 | 432 | Novartis PharmaceuticalsINDUSTRY | 22 | Jan 30, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. | completed | Phase 3 | 1,099 | Millennium Pharmaceuticals, Inc.INDUSTRY | 14 | Dec 19, 2018 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT00838201 | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer | completed | Phase 3 | 384 | AmgenINDUSTRY | 6 | Oct 18, 2018 | clinicaltrials |
| NCT01305655 | Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL(NOPHOCPG2) | completed | Phase 3 | 47 | Nordic Society for Pediatric Hematology and OncologyOTHER | 5 | Sep 28, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
| NCT00122681 | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 | completed | Phase 3 | 18,729 | GlaxoSmithKlineINDUSTRY | 14 | Aug 20, 2018 | clinicaltrials |
| NCT00552058 | Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | completed | Phase 3 | 439 | UCB PharmaINDUSTRY | 20 | Aug 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials